NASDAQ:PCRX

Pacira BioSciences Stock Forecast, Price & News

$60.08
+0.07 (+0.12 %)
(As of 07/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$59.99
$61.93
50-Day Range
$55.30
$66.48
52-Week Range
$48.23
$80.00
Volume307,301 shs
Average Volume456,676 shs
Market Capitalization$2.65 billion
P/E Ratio18.10
Dividend YieldN/A
Beta1.07
30 days | 90 days | 365 days | Advanced Chart
Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.


Pacira BioSciences logo

About Pacira BioSciences

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.02 out of 5 stars

Medical Sector

250th out of 2,214 stocks

Pharmaceutical Preparations Industry

128th out of 869 stocks

Analyst Opinion: 3.4Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 3.1 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Pacira BioSciences (NASDAQ:PCRX) Frequently Asked Questions

Is Pacira BioSciences a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Pacira BioSciences stock.
View analyst ratings for Pacira BioSciences
or view top-rated stocks.

What stocks does MarketBeat like better than Pacira BioSciences?

Wall Street analysts have given Pacira BioSciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pacira BioSciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Pacira BioSciences' next earnings date?

Pacira BioSciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Pacira BioSciences
.

How can I listen to Pacira BioSciences' earnings call?

Pacira BioSciences will be holding an earnings conference call on Tuesday, August 3rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "9991311".

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) announced its quarterly earnings results on Monday, May, 3rd. The company reported $0.53 EPS for the quarter, missing analysts' consensus estimates of $0.64 by $0.11. The company earned $119 million during the quarter, compared to analysts' expectations of $119.23 million. Pacira BioSciences had a trailing twelve-month return on equity of 11.09% and a net margin of 33.35%. Pacira BioSciences's quarterly revenue was up 12.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.53 earnings per share.
View Pacira BioSciences' earnings history
.

How has Pacira BioSciences' stock price been impacted by COVID-19 (Coronavirus)?

Pacira BioSciences' stock was trading at $35.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PCRX stock has increased by 70.7% and is now trading at $60.08.
View which stocks have been most impacted by COVID-19
.

What guidance has Pacira BioSciences issued on next quarter's earnings?

Pacira BioSciences issued an update on its second quarter 2021 earnings guidance on Tuesday, July, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135.60 million-$135.60 million, compared to the consensus revenue estimate of $128.01 million.

What price target have analysts set for PCRX?

11 analysts have issued 12-month price objectives for Pacira BioSciences' stock. Their forecasts range from $65.00 to $94.00. On average, they expect Pacira BioSciences' share price to reach $78.31 in the next year. This suggests a possible upside of 30.3% from the stock's current price.
View analysts' price targets for Pacira BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Pacira BioSciences' key executives?

Pacira BioSciences' management team includes the following people:
  • David M. Stack, Chairman, Chief Executive & Operating Officer
  • Charles A. Reinhart, Chief Financial Officer
  • Roy Winston, Chief Clinical Officer
  • Charles Anthony Laranjeira, Chief Technical Officer
  • Kristen Marie Williams, Secretary & Chief Administrative Officer

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences CEO Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among Pacira BioSciences' employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Pacira BioSciences' key competitors?

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

What is Pacira BioSciences' stock symbol?

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by many different retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.30%), Gradient Investments LLC (0.14%), Legacy Capital Partners Inc. (0.09%), State of Alaska Department of Revenue (0.07%) and Outfitter Financial LLC (0.05%). Company insiders that own Pacira BioSciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, Donald C Manning, John P Phd Longenecker, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends for Pacira BioSciences
.

Which major investors are selling Pacira BioSciences stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including Outfitter Financial LLC, and Legacy Capital Partners Inc.. Company insiders that have sold Pacira BioSciences company stock in the last year include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Donald C Manning, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, and Roy Winston.
View insider buying and selling activity for Pacira BioSciences
or view top insider-selling stocks.

Which major investors are buying Pacira BioSciences stock?

PCRX stock was purchased by a variety of institutional investors in the last quarter, including Scout Investments Inc., Gradient Investments LLC, and State of Alaska Department of Revenue.
View insider buying and selling activity for Pacira BioSciences
or or view top insider-buying stocks.

How do I buy shares of Pacira BioSciences?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacira BioSciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $60.08.

How much money does Pacira BioSciences make?

Pacira BioSciences has a market capitalization of $2.65 billion and generates $429.65 million in revenue each year. The company earns $145.52 million in net income (profit) each year or $1.30 on an earnings per share basis.

How many employees does Pacira BioSciences have?

Pacira BioSciences employs 624 workers across the globe.

What is Pacira BioSciences' official website?

The official website for Pacira BioSciences is www.pacira.com.

Where are Pacira BioSciences' headquarters?

Pacira BioSciences is headquartered at 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054.

How can I contact Pacira BioSciences?

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at (973) 254-3560 or via email at [email protected]


This page was last updated on 7/30/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.